Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -0.78 is 54% above its 5-year average of -1.68, near the high end of its 5-year range (-2.35–-0.78).
33.33% above its 12-month average of -1.17.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.12.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T12:00:57.276Z. Historical observations retain their original dates. Historical series through 2018-03-29.
EARNINGS PER SHARE (EPS)
-0.78
EARNINGS PER SHARE (EPS) AVG TTM
-1.17
EARNINGS PER SHARE (EPS) AVG 3Y
-1.45
EARNINGS PER SHARE (EPS) AVG 5Y
-1.68
EARNINGS PER SHARE (EPS) AVG 10Y
-15.05
EARNINGS PER SHARE (EPS) AVG 15Y
-16.74
EARNINGS PER SHARE (EPS) AVG 20Y
-18.18
CURRENT VS TTM AVG
+33.33%
CURRENT VS 3Y AVG
+46.30%
CURRENT VS 5Y AVG
+53.53%
CURRENT VS 10Y AVG
+94.82%
CURRENT VS 15Y AVG
+95.34%
CURRENT VS 20Y AVG
+95.71%
Altimmune, Inc.
Market Cap
$519.25M
Earnings Per Share (EPS)
-0.78
TTM Avg
-1.17
3Y Avg
-1.45
5Y Avg
-1.68
Market Cap
$517.79M
Earnings Per Share (EPS)
-7.58
TTM Avg
-39.00
3Y Avg
-56.28
5Y Avg
-76.67
Market Cap
$517.73M
Earnings Per Share (EPS)
-0.67
TTM Avg
-1.09
3Y Avg
-1.67
5Y Avg
-1.68
Market Cap
$491.93M
Earnings Per Share (EPS)
-0.52
TTM Avg
-0.81
3Y Avg
-1.01
5Y Avg
-1.63
Market Cap
$491.55M
Earnings Per Share (EPS)
-1.98
TTM Avg
-3.65
3Y Avg
-4.15
5Y Avg
-2.79
Market Cap
$547.86M
Earnings Per Share (EPS)
0.01
TTM Avg
0.08
3Y Avg
-2.02
5Y Avg
-4.00
Market Cap
$487.30M
Earnings Per Share (EPS)
-1.99
TTM Avg
-0.88
3Y Avg
-1.91
5Y Avg
-1.95
Market Cap
$481.33M
Earnings Per Share (EPS)
0.16
TTM Avg
-2.02
3Y Avg
-3.99
5Y Avg
-3.80
Market Cap
$478.54M
Earnings Per Share (EPS)
-1.73
TTM Avg
-1.90
3Y Avg
-1.16
5Y Avg
-1.16
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Altimmune, Inc. (ALT) | $519.25M | -0.78 | -1.17 | -1.45 | -1.68 |
| Crescent Biopharma, Inc. (CBIO)vs › | $517.79M | -7.58 | -39.00 | -56.28 | -76.67 |
| Allogene Therapeutics, Inc. (ALLO)vs › | $517.73M | -0.67 | -1.09 | -1.67 | -1.68 |
| Evolus, Inc. (EOLS)vs › | $491.93M | -0.52 | -0.81 | -1.01 | -1.63 |
| NeoGenomics, Inc. (NEO)vs › | $491.55M | -1.98 | -3.65 | -4.15 | -2.79 |
| Delcath Systems, Inc. (DCTH)vs › | $547.86M | 0.01 | 0.08 | -2.02 | -4.00 |
| Bright Minds Biosciences Inc. (DRUG)vs › | $487.30M | -1.99 | -0.88 | -1.91 | -1.95 |
| Arvinas, Inc. (ARVN)vs › | $481.33M | 0.16 | -2.02 | -3.99 | -3.80 |
| Contineum Therapeutics, Inc. (CTNM)vs › | $478.54M | -1.73 | -1.90 | -1.16 | -1.16 |
| CytomX Therapeutics, Inc. (CTMX)vs › | $561.67M | -0.45 | 0.12 | -0.31 | -0.31 |
Trailing EPS (TTM)
$-0.78
Forward EPS (Est.)
$-0.58
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -1.00 |
| 2024-12-31 | -1.34 |
| 2023-12-31 | -1.66 |
| 2022-12-31 | -1.81 |
| 2021-12-31 | -2.35 |
| 2020-12-31 | -1.91 |
| 2019-12-31 | -1.56 |
| 2018-12-31 | -13.98 |
| 2017-12-31 | -108.77 |
| 2015-12-31 | -16.13 |
| 2014-12-31 | -51.91 |
| 2013-12-31 | -69.40 |
| 2012-12-31 | -30.55 |
| 2011-12-31 | -24.07 |
| 2010-12-31 | -323.59 |
| 2009-12-31 | -351.19 |
| 2008-12-31 | -476.15 |
| 2007-12-31 | -431.69 |
| 2006-12-31 | 23.63 |
| 2005-12-31 | 12.00 |
